Regensight srl has been awarded the grant application prot. n. A0122-2020-35929 under the “PRE-SEED” public tender – POR FESR LAZIO 2014 – 2020.(www.europa.eu; e http://www.lazioinnova.it/bandi-post/pre-seed-sostegno-alla-creazione-al-consolidamento-startup-innovative-ad-alta-intensita-applicazione-conoscenza-alle-iniziative-spin-off-della-ricerca/)
This grant has been awarded for the activities related to the project entitled: “Development of a non-invasive surgical platform for the visual correction of keratoconus”.
The main purpose of the project is to develop a pre-series batch of ten UV-A medical devices to accelerate the clinical research activities for validating the theranostics paradigm for the treatment of keratoconus.
The realization of the project objectives will allow Regensight to seize the opportunity to accelerate its entry into the market and lay the foundations to become one of the main world players
committed to reducring the social burden of treatment of keratoconus.
The results will be presented as soon as they are available. The project started on December 3, 2020 and will end by December 2, 2021.
The maximum concession grant relating to the “Pre-seed” call is € 100,000.
Indication of interest for investments can be considered from Venture Capital investors, Public Investors, Corporate Investors, Business Angels, and/or private investors.